Novo Nordisk Could Benefit From Latest Fda Warning | Latest News RSS feed

Novo Nordisk Could Benefit From Latest Fda Warning - Latest News


Novo Nordisk Could Benefit From Latest FDA Warning

The FDA recently issued a warning about the linking of Fournier's gangrene with SGLT2 inhibitors used in the treatment of type-2 diabetes. Novo Nordisk claims that its GLP-1 analogues are better at tr... read more

Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

Eli Lilly has cardiovascular outcome data for its diabetes drug Trulicity that could help it fend off a challenge from Novo Nordisk’s Ozempic ... Trulicity the first type 2 diabetes drug to show a ben... read more

U.S. FDA panel: Novo Nordisk's liraglutide safe, effective for obesity

According to analysts, it could generate $1 billion in revenue for the company. The FDA typically follows the recommendations of its advisory panels. Just before the vote, Novo Nordisk shares rose 1.8 ... read more

Looking for another news?


The FDA Throws Novo Nordisk Off Course

When I wrote on Novo ... is developing a new follow-on to Lantus. Both of these are most likely to be 2015 launches. There is also the risk of competition from biosimilars, but I would argue that the ... read more


FDA panel recommends approval of Novo Nordisk diabetes drug

The FDA is not obliged ... to start a patient on two new drugs at once. But certain patients in this group, such as those who were needle-shy, could benefit, they said. Dr. Todd Hobbs, U.S. chief medi... read more

Novo Nordisk: Strict US regulation threatens innovation

A stricter application of new medicine regulations in the US is threatening pharma innovation, according to Novo Nordisk's CEO Lars ... US due to safety issues. It could now be two years before Novo i... read more

Lilly’s Trulicity diabetes drug cuts risk of CV events in lower-risk patient group

A glucagon-like peptide (GLP-1) agonist class drug, Trulicity (dulaglutide) is under threat in the US from Novo Nordisk ... will not show a benefit. Lilly will submit the latest data to regulators ... read more

Novo Nordisk builds R&D capacity in cardiovascular and liver diseases

Subsequently, the FDA approved the medication for CVD-related indications for patients with type 2 diabetes. Results from investigator-sponsored trials and Novo Nordisk ... new drug targets. “If peopl... read more

Novo Nordisk takes aim at Eli Lilly with U.S. backing of new diabetes drug

WASHINGTON/COPENHAGEN, Oct 19 (Reuters) - Denmark's Novo Nordisk will take aim at Eli ... that the drug's label will to carry a standard warning, similar to insulins, regarding diabetic retinopathy. T... read more

Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million

"At Novo Nordisk, we take our responsibility to communicate the safety and clinical benefits of our medicines ... which gained FDA approval in 2010. Victoza's FDA-approved labeling also contained a bo... read more

Novo, Sanofi go head to head as FDA clears new diabetes drugs

(Reuters) - Rivals Novo Nordisk and Sanofi have won U.S. approval for new combination drugs to treat diabetes ... so there were lots of patients who could benefit. Achieving Xultophy's full potential ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us